The Study of Koebner in Patients With Psoriasis and Psoriatic Arthritis (PSODEEP1)

Skane University Hospital

Status: Completed

Conditions: Psoriasis; Koebner Phenomenon; Psoriasis; Arthritis (Etiology)

Study type: Observational

Funder types: Other

Identifiers

NCT05589298

PSODEEP1

Details and patient eligibility

About

PSODEEP 1 is a descriptive digital interview study where we intend to include at least 900 individuals. Individuals with known psoriasis or known psoriatic arthritis will access the digital interview via a QR code distributed via their rheumatology or dermatology department using their smartphones. Data on answers results are stored digitally and can be accessed parallel to recruitment. Questions focus on following fields (all self reported): background information (age/sex), disease duration, disease course/fluctuation, disease diagnosis as given by MD, disease treatment, disease severity, disease classification, disease triggers, screening of psoriatic arthritis (questions derived from PEST questionnaire), Koebner occurence, variability in Koebner over time, deep-Koebner occurence and variability in Deep-Koebner over time.

Full description

PSODEEP1 is a descriptive digital interview study. Questions on self reported experience of following fields will be stated: background information, disease duration, disease course/fluctuation, disease diagnosis as given by MD, disease treatment, disease severity, disease classification, disease triggers, screening of psoriatic arthritis (questions derived from PEST questionnaire), Koebner occurence, variability in Koebner over time, deep-Koebner occurence and variability in Deep-Koebner over time.

Questions will be distributed using REDCap (REsearch Electronic Data CAPture) platform provided by Lunds university, University of Santiago and Copenhagen University (www.project-redcap.org). Patients with known psoriasis or psoriatic arthritis will reach the questionnaire using a QR-code on patient's information sheet distributed in clinical settings. In Sweden, patients will be recruited at dermatology and rheumatology outpatient clinics in Malmö, Lund, Göteborg, Örebro, Stockholm (Skåne University Hospital, Karolinska Hospital, Sahlgrenska Hospital, Ryhov Hospital, Örebro, Hospital). In Chile patients will be recruited at Hospital Clínico Universidad de Chile and CIEC-PMR Centro Internacional de Estudios Clínicos - Probity Medical Research. In Denmark, patients will be recruited at Gentofte Hospital and through Leo foundation skin immunology research center (Copenhagen University) and the Parker Institute.

Study inclusion criteria: Physician diagnosed psoriasis, psoriatic arthritis or both. Age of 18 years or older. Ability to comprehend instructions and read the Swedish, Spanish or Danish language (according to country). Having a smartphone with which one can access the study questions using a QR code. Study exclusion criteria: Having participated in the study already. Not having a mobile telephone number (used to identify duplicate answers).

Enrollment: 3,064 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• MD diagnosis of psoriasis and/or psoriasis arthritis
• Age over 18 years
• Ability to read and understand written questions
• Having/ability to use smartphone
• Given consent

Exclusion criteria

• Having participated previously

Trial design

3,064 participants in 4 patient groups

PSODEEP1 Sweden

Description:

Patients with self reported MD given diagnosis of psoriasis and/or psoriatic arthritis in Sweden.

PSODEEP1 Denmark

Description:

Patients with self reported MD given diagnosis of psoriasis and/or psoriatic arthritis in Denmark.

PSODEEP1 Chile

Description:

Patients with self reported MD given diagnosis of psoriasis and/or psoriatic arthritis in Chile.

PSODEEP1 Netherlands

Description:

Patients with self reported MD given diagnosis of psoriasis and/or psoriatic arthritis in the Netherlands.